Search Results

• • 1 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• A phase I open-label study of the safety and efficacy of apatinib (rivoceranib) administered to patients with advanced malignancies to improve sensitivity to pembrolizumab in the second- or later-line setting (APPEASE).

  Authors:Matthew Gumbleton, Stephanie Allan, Hannah Conway, Kenneth Boucher, James Marvin, Josiah Hawks, et al.From:BMC Research Notes (Vol. 16, Issue 1) Peer-Reviewed

  Feb. 16, 20233,101 words Report 1480LObjective APPEASE is a phase I study to assess the safety, dosing, and efficacy of rivoceranib (a selective, small-molecule inhibitor of VEGFR2) in combination with pembrolizumab. We aimed to treat patients with...